Peter Dutton (Dickson, Liberal Party, Shadow Minister for Health and Ageing) Share this | Hansard source

asked the Minister for Health and Ageing, in writing, on 3 March 2011:

In respect of the medicines Duodart, Invega Sustenna, Targin, Symbicort, Botox, Fragmin and Synarel that were recommended for listing on the Pharmaceutical Benefits Scheme (PBS) by the Pharmaceutical Benefits Advisory Committee (PBAC), but deferred by the Australian Government:

(a) why was the listing of these medicines deferred;

(b) what advice was the decision to defer the listing of these medicines based upon;

(c) what is the projected cost per annum to the Commonwealth of listing each medicine;

(d) what is the saving to the Government over the forward estimates of deferring the listing of these medicines;

(e) can she indicate

(i) which medicines were considered by Cabinet: and

(ii) the estimated length of time of the deferral of the listing of these medicines; and

(f) how many people are projected to be prescribed each medicine in the first year of them being listing.

See this speech in context